JP2012523838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523838A5 JP2012523838A5 JP2012505990A JP2012505990A JP2012523838A5 JP 2012523838 A5 JP2012523838 A5 JP 2012523838A5 JP 2012505990 A JP2012505990 A JP 2012505990A JP 2012505990 A JP2012505990 A JP 2012505990A JP 2012523838 A5 JP2012523838 A5 JP 2012523838A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sample
- nos
- subject
- marker genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 26
- 239000000523 sample Substances 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 239000003550 marker Substances 0.000 claims 13
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 229940123189 CD40 agonist Drugs 0.000 claims 5
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 3
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 claims 3
- 101001012021 Homo sapiens Mammalian ependymin-related protein 1 Proteins 0.000 claims 3
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 claims 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 3
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 claims 3
- 102100030031 Mammalian ependymin-related protein 1 Human genes 0.000 claims 3
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 3
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims 2
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 2
- 101000793922 Homo sapiens Dipeptidyl peptidase 1 Proteins 0.000 claims 2
- 101000854774 Homo sapiens Pantetheine hydrolase VNN2 Proteins 0.000 claims 2
- 101000933604 Homo sapiens Protein BTG2 Proteins 0.000 claims 2
- 101000590549 Homo sapiens Pseudouridylate synthase 7 homolog Proteins 0.000 claims 2
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102100020748 Pantetheine hydrolase VNN2 Human genes 0.000 claims 2
- 102100026034 Protein BTG2 Human genes 0.000 claims 2
- 102100032494 Pseudouridylate synthase 7 homolog Human genes 0.000 claims 2
- 238000011529 RT qPCR Methods 0.000 claims 2
- 101710148333 Regulator of G-protein signaling 13 Proteins 0.000 claims 2
- 102100021035 Regulator of G-protein signaling 18 Human genes 0.000 claims 2
- 102100023876 Rhombotin-2 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000013074 reference sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17061509P | 2009-04-18 | 2009-04-18 | |
| US61/170,615 | 2009-04-18 | ||
| PCT/US2010/031528 WO2010121231A1 (en) | 2009-04-18 | 2010-04-17 | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523838A JP2012523838A (ja) | 2012-10-11 |
| JP2012523838A5 true JP2012523838A5 (enExample) | 2013-06-06 |
| JP5836929B2 JP5836929B2 (ja) | 2015-12-24 |
Family
ID=42358184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505990A Active JP5836929B2 (ja) | 2009-04-18 | 2010-04-17 | 抗ｃｄ４０抗体を用いる治療に対するｂ細胞性リンパ腫の応答性を評価するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9617600B2 (enExample) |
| EP (1) | EP2419531B1 (enExample) |
| JP (1) | JP5836929B2 (enExample) |
| KR (1) | KR101787768B1 (enExample) |
| CN (1) | CN102459639A (enExample) |
| AU (1) | AU2010236168B2 (enExample) |
| BR (1) | BRPI1011394A8 (enExample) |
| CA (1) | CA2758523C (enExample) |
| ES (1) | ES2605228T3 (enExample) |
| IL (1) | IL215707A (enExample) |
| MX (1) | MX2011010938A (enExample) |
| WO (1) | WO2010121231A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820707A2 (pt) | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| ES2634254T3 (es) | 2011-09-12 | 2017-09-27 | Atrys Health, SA | Métodos para el pronóstico del linfoma difuso de linfocitos B grandes |
| HUE049569T2 (hu) | 2012-08-09 | 2020-09-28 | Celgene Corp | Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| EP2914627B1 (en) | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| TWI794885B (zh) | 2014-05-19 | 2023-03-01 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2022120038A1 (en) * | 2020-12-02 | 2022-06-09 | Albert Einstein College Of Medicine | Method for predicting patient response to cd40-targeted therapies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
| IL151865A0 (en) | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| WO2002078766A2 (en) | 2001-04-02 | 2002-10-10 | Genentech, Inc. | Combination therapy |
| JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| RS53073B (sr) | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| SI1682177T1 (sl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije |
| CA2848463A1 (en) * | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| JP5421590B2 (ja) * | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| ATE485057T1 (de) * | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| JP5904569B2 (ja) * | 2005-06-08 | 2016-04-13 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療を受けている患者の同定、判定および処置のための方法 |
| JP2009508484A (ja) * | 2005-09-16 | 2009-03-05 | バイオベイター・テクノロジーズ・アクチボラゲット | アレルゲン性タンパク質の同定のためのインビトロアッセイ |
| DE102005052384B4 (de) * | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens |
| MX2008007140A (es) | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Metodos para utilizar agentes de union a cd40. |
| US7527774B2 (en) | 2005-12-22 | 2009-05-05 | Basf Catalysts Llc | Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms |
| EP1987161A4 (en) * | 2006-01-20 | 2009-06-24 | Univ Mcgill | METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS |
| RU2473555C2 (ru) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| BRPI0820707A2 (pt) * | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
-
2010
- 2010-04-17 US US13/264,973 patent/US9617600B2/en active Active
- 2010-04-17 EP EP10715067.4A patent/EP2419531B1/en active Active
- 2010-04-17 BR BRPI1011394A patent/BRPI1011394A8/pt active Search and Examination
- 2010-04-17 KR KR1020117027354A patent/KR101787768B1/ko active Active
- 2010-04-17 JP JP2012505990A patent/JP5836929B2/ja active Active
- 2010-04-17 CA CA2758523A patent/CA2758523C/en active Active
- 2010-04-17 MX MX2011010938A patent/MX2011010938A/es active IP Right Grant
- 2010-04-17 CN CN201080027267XA patent/CN102459639A/zh active Pending
- 2010-04-17 ES ES10715067.4T patent/ES2605228T3/es active Active
- 2010-04-17 AU AU2010236168A patent/AU2010236168B2/en not_active Ceased
- 2010-04-17 WO PCT/US2010/031528 patent/WO2010121231A1/en not_active Ceased
-
2011
- 2011-10-11 IL IL215707A patent/IL215707A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523838A5 (enExample) | ||
| JP2011504102A5 (enExample) | ||
| Gupta et al. | Cell-based biosensors: Recent trends, challenges and future perspectives | |
| Landt et al. | ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia | |
| ES2905579T3 (es) | Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama | |
| JP6664011B2 (ja) | サンプル中のポリヌクレオチド配列のための存在量パラメータの決定 | |
| JP7157788B2 (ja) | 膵・消化管神経内分泌新生物の診断のための組成物、方法およびキット | |
| JP2014509868A5 (enExample) | ||
| JP2013521763A5 (enExample) | ||
| JP2008536488A5 (enExample) | ||
| CA2798593A1 (en) | Methods and kits for diagnosing colorectal cancer | |
| JP2009526519A5 (enExample) | ||
| JPWO2018056432A1 (ja) | 血液検体の溶血を検出する方法及び溶血検出用チップ | |
| Ensafi et al. | A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia | |
| CN109182517A (zh) | 一组用于髓母细胞瘤分子分型的基因及其应用 | |
| AU2022340811A1 (en) | Assessment of melanoma therapy response | |
| JPWO2020027098A1 (ja) | 体液検体の品質評価方法 | |
| CN103451268B (zh) | 一种检测线粒体a3243g杂合突变率的标准品、试剂盒及其检测方法 | |
| JP2008518598A5 (enExample) | ||
| EP2499261A2 (en) | Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes | |
| Zhang et al. | A “dual-signal-on” fluorescence-electrochemical biosensor for miRNA detection based on CHA-HCR-CRISPR/Cas12a cascade amplification and SDR switch | |
| CN101666805A (zh) | 特异性蛋白检测芯片的制备方法 | |
| CN114566224B (zh) | 一种用于鉴别或区分不同海拔人群的模型及其应用 | |
| CN107043809B (zh) | 一种猪等孢球虫qRT-PCR定量检测构建方法 | |
| CN114032308B (zh) | Fam83a、kpna2、krt6a和ldha联合作为肺腺癌生物标志物的用途 |